Frequently asked questions (FAQs)


TASCENSO ODT is the same proven fingolimod you are familiar with, but it comes in an orally disintegrating tablet (ODT) formulation.1

TASCENSO ODT’s unique formulation can be taken with or without water and dissolves in seconds.

The tablet is taken once daily, with or without food.1

Find out more

Under the FDA’s 505(b)(2) pathway, TASCENSO ODT was shown to have the same pharmacokinetics (PK) as Gilenya® (fingolimod) capsules, meaning the rate and extent of exposure of the drug is the same for both formulations. Therefore, the two products are considered bioequivalent.3

TASCENSO ODT demonstrated a similar lowering of lymphocyte counts and effect on heart rate as Gilenya®.3

Find out more

TASCENSO ODT is not a generic.4

It has the same safety, efficacy and side effects as Gilenya® (fingolimod) capsules and other generic fingolimod products, but it comes in a unique orally disintegrating tablet formulation.1

TASCENSO ODT is not substitutable (AB rated) to any other product, because it has a unique formulation, which could better suit your patients’ needs.3 Generic fingolimod products are not substitutable (AB rated) to TASCENSO ODT either.3

It is also accompanied by Cycle Vita™, our support platform.*

Find out more about TASCENSO ODT’s data
Find out more about Cycle Vita

Fingolimod blocks lymphocytes from leaving the lymph node, reducing the number of lymphocytes in the blood.1

It is thought this may reduce lymphocyte migration into the central nervous system.1

During a study of TASCENSO ODT:

  • 89% of participants agreed they had an overall favorable opinion of TASCENSO ODT.4
  • All participants felt TASCENSO ODT left a pleasant taste.4
  • 82% of participants agreed TASCENSO ODT had no bitter after-taste.4

Find out more

You can print and send an enrollment form to Cycle Vita at or fax it to them at + 1 (888) 385-8482.

Find out more

With TASCENSO ODT, no special storage conditions are required, the product should be stored at room temperature (68°F to 77°F) and protected from moisture.1

Patients should take the TASCENSO ODT immediately after opening the blister pack and should not store it outside the blister pack for future use.

Find out more about taking TASCENSO ODT

TASCENSO ODT may harm an unborn baby.1 Patients should avoid getting pregnant whilst taking TASCENSO ODT and for two months after stopping TASCENSO ODT treatment.1

Read the Prescribing Information

TASCENSO ODT is different to other tablets to allow for quick dissolving. It is lightly adhered to the blister pack wall and a very small amount of product residue may remain inside the pack which can cause a slightly feathered edge. This is nothing to worry about and your patients will still receive the correct dose.

Patients should use dry hands when opening the blister pack and peel back the foil covering of 1 blister pack. They should gently remove the orally disintegrating tablet (ODT) and make sure not to push the ODT through the foil.

As soon as the blister pack is opened, the ODT should be removed and placed on the tongue, allowing it to dissolve. TASCENSO ODT should not be stored outside the blister pack for future use.

Read more

Cycle Pharmaceuticals manufactures TASCENSO ODT in the UK, with each and every batch tested and verified.

Finance and Insurance

For eligible* patients taking another fingolimod treatment, a free supply of TASCENSO ODT is available to ensure the continuation of therapy while Cycle Vita secures appropriate benefit verification and prior authorization.

The Bridge Program may also be requested for existing TASCENSO ODT patients who are temporarily experiencing disruption in therapy due to insurance coverage.

Find out more

Eligible* patients who are switching to TASCENSO ODT from another fingolimod treatment will have access to our Bridge Program while Cycle Vita secures appropriate benefit verification and prior authorization.

It is available to patients with an urgent medical need for TASCENSO ODT, including:

  • For new patients who are switching to TASCENSO ODT from another fingolimod treatment while Cycle Vita secures appropriate benefit verification and prior authorization, providing they have not had a lapse of two weeks or more in their medication.
  • For existing patients who are experiencing a temporary disruption in TASCENSO ODT therapy due to changes in their insurance coverage.

If your patient’s insurance situation changes, the patient must notify Cycle Vita immediately at 1-+1 (888) 360-8482.

Find out more

Commercially insured eligible patients who have been prescribed TASCENSO ODT may pay as little as $0 in co-pay.*

To find out more about eligibility criteria please contact Cycle Vita on +1 (888) 360-8482.

Find out more

Baseline assessments may include:

  • Blood work
  • An ECG
  • An eye exam
  • Liver enzymes
  • Vaccinations if needed

Find out more

Yes, eligible* patients will have access to additional first dose observations required due to a lapse in therapy via the TASCENSO Time Program.

Find out more

Getting Started

Complete a TASCENSO ODT enrollment form and either email it to our Cycle Vita team at or fax it to them at + 1 (888) 385-8482.

Once they receive the form, our expert team will take care of all the details so your patients can get started on their treatment as soon as possible.

Please use the enrollment form rather than your own prescription form to avoid delays.  You can use the Rx Checklist to help you complete the enrollment form correctly. And remember to specify dispense as written (DAW) on every enrollment form to ensure that your patients receive TASCENSO ODT and the support available through Cycle Vita.

Rx checklist

Eligible* patients who are switching to TASCENSO ODT from another fingolimod treatment will have access to our Bridge Program while Cycle Vita secures appropriate benefit verification and authorization.

Find out more

Patients who are switching from another fingolimod treatment to TASCENSO ODT should not take both treatments at the same time. Once your patient starts TASCENSO ODT they should stop taking any other fingolimod treatment.

Read the Prescribing Information

Our priority is to ensure patients experience a smooth transition from their current disease modifying therapy (DMT) to TASCENSO ODT.

For patients currently taking the same dose (0.25 mg or 0.5 mg) of another fingolimod treatment a FDO will not be required, providing the patient has not had a lapse in treatment for 14 days or more.1

Patients who are currently not on another fingolimod treatment or are increasing their fingolimod dose (from 0.25 mg to 0.5 mg) will need to have baseline assessments (BA) and a FDO to initiate therapy. 1

Find out more

Cycle Vita

The Cycle Vita team are just a phone call away. You can expect to hear from two types of people at Cycle Vita:

  • Access Specialists – help you access TASCENSO ODT through enrollment, financial and pharmacy support*
  • Clinical Specialists – provide clinical education, clinical support and medication administration support*

+1 (888) 360-8482

Yes, our registered clinicians, who have decades of experience supporting patients with MS, can provide disease state and medication training to facilitate adherence.

Find out more

As soon as Cycle Vita receives a completed enrollment form, we can provide individualized support to eligible* patients, such as access to treatment, financial and pharmacy support, as well as clinical education and medication administration support. We will reach out to you and your patient in order to take the next steps.

Find out more


1. TASCENSO ODT (0.25 mg) Prescribing Information. Cycle Pharmaceuticals Ltd.
2. Data on file: REF-00064.
3. Data on file: REF-00075.
4. Data on file: REF-00068.

*Some areas of support may not be accessible to all patients. Eligibility criteria may apply to ensure compliance with all applicable federal and state requirements, and benefits may be limited to commercially insured patients only. For more detailed information about eligibility, terms and conditions, please contact the Cycle Vita team at +1 (888) 360-8482.

TASCENSO ODT® is a registered trademark of Handa Neuroscience, LLC.

Cycle Vita™ is a trademark of Cycle Pharmaceuticals Ltd.

Gilenya® is a registered trademark of Novartis AG.

Tascenso ODT Logo
Tascenso Logo

TASCENSO ODT is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older.

  • Patients who in the last 6 months experienced myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure with hospitalization, or Class III/IV heart failure.
  • Patients with a history or presence of Mobitz Type II 2nd degree or 3rd degree AV block or sick sinus syndrome, unless patient has a functioning pacemaker.
  • Patients with a baseline QTc interval ≥ 500 msec.
  • Patients with cardiac arrhythmias requiring anti-arrhythmic treatment with Class Ia or Class III anti-arrhythmic drugs.
  • Patients who had a hypersensitivity to fingolimod or any excipients in TASCENSO ODT.
  • Concomitant use with other products containing fingolimod.

Important Safety Information

Warnings and Precautions:

Due to a risk for bradyarrhythmia and AV blocks patients should be monitored during TASCENSO ODT treatment initiation. TASCENSO ODT may increase blood pressure, risk of infections and may cause fetal harm. Cases of Progressive Multifocal Leukoencephalopathy and of clinically significant liver injury have occurred in patients treated with fingolimod in the postmarketing setting. TASCENSO ODT increases risk of macular edema. Rare cases of Posterior Reversible Encephalopathy Syndrome in adults have been reported with fingolimod.  Fingolimod can have respiratory effects. Severe increase in disability accompanied by multiple new lesions on MRI has been reported following discontinuation of fingolimod. MS relapses with tumefactive demyelinating lesions on imaging have been observed during fingolimod therapy and after discontinuation. The risk of basal cell carcinoma and melanoma is increased in patients treated with fingolimod. Cases of lymphoma have been reported in patients receiving fingolimod. The reporting rate of non-Hodgkin lymphoma with fingolimod is greater than that expected in the general population. Fingolimod remains in the blood and has pharmacodynamic effects, including decreased lymphocyte counts for up to 2 months following the last dose. Hypersensitivity reactions including rash, urticaria, and angioedema have been reported with fingolimod. Cases of seizures, including status epilepticus, have been reported with the use of fingolimod.

Adverse Reactions:

In clinical trials, the most common adverse reactions (incidence ≥ 10% and >placebo) are headache, liver transaminase elevation, diarrhea, cough, influenza, sinusitis, back pain, abdominal pain, and pain in extremity.

Drug Interactions:

Patients on QT prolonging drugs with a known risk of torsades de pointes should be monitored during initiation of treatment with TASCENSO ODT. Monitor patients during use of systemic ketoconazole. Use of live attenuated vaccines during, and for 2 months after stopping TASCENSO ODT, should be avoided.

For more detailed information, please refer to the full Prescribing Information at

To report SUSPECTED ADVERSE REACTIONS, contact Cycle Pharmaceuticals Ltd at 1-888-533-1625 or the FDA at: 1-800-FDA-1088 or


©2023 Cycle Pharmaceuticals Limited. All rights reserved.

TASCENSO ODT® is a registered trademark of Handa Neuroscience, LLC.

Cycle Vita is a trademark of Cycle Pharmaceuticals Limited in the United States.

Follow us




Cycle Vita USA

US-FIN-2300111 | Date of Preparation: June 2023